BlossomHill Therapeutics, Inc.
BLSM
$16.18
-$0.17-1.04%
NASDAQ
| 03/31/2026 | |||||
|---|---|---|---|---|---|
| Net Income | -100.50% | ||||
| Total Depreciation and Amortization | 47.06% | ||||
| Total Amortization of Deferred Charges | -- | ||||
| Total Other Non-Cash Items | 58.05% | ||||
| Change in Net Operating Assets | 29.22% | ||||
| Cash from Operations | -90.73% | ||||
| Capital Expenditure | 96.77% | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | -- | ||||
| Cash from Investing | 96.77% | ||||
| Total Debt Issued | -- | ||||
| Total Debt Repaid | -- | ||||
| Issuance of Common Stock | 602.56% | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | -- | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | -- | ||||
| Cash from Financing | 602.56% | ||||
| Foreign Exchange rate Adjustments | -- | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | -82.32% | ||||